OKUR · CIK 0001637715 · operating
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology medicines targeting genetically validated cancer drivers. The company's lead program, OKI-219, is a selective inhibitor of phosphoinositide 3-kinase alpha (PI3K-alpha) designed to target tumors harboring the H1047R mutation. OKI-219 is currently in Phase 1 clinical development for solid tumors, with an initial focus on breast cancer indications.
The company operates as a research and development organization without disclosed revenue streams, as it has not advanced products to commercial stage. OnKure maintains its headquarters in Boulder, Colorado, with a team of 46 full-time employees. The organization is incorporated in Delaware and trades on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-15.28 | $-15.28 | -506.3% | |
| 2023 | $-2.52 | $-2.52 | -18.9% | |
| 2022 | $-2.12 | $-2.12 | +3.2% | |
| 2021 | $-2.19 | $-2.19 | — |